Epidemiology data show that there are approximately 40 million people worldwide who are thought to have AD [19], and the number of people with PD is expected to increase by 9 million by 2030 [20], suggesting that ADAR1 dysfunction may contribute to a broad disease burden. This evidence concerns the gene ADAR and Parkinson disease.